Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in RRMS patients with neutralizing antibodies to Interferon Beta
NCT01621269Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Primary endpoint: Number of patients with active MRI lesions at 12 months. Planned start Jun 2013; status: withdrawn.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01621269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621269.